To further explore the underlying mechanism by which anlotinib inhibited cisplatin-resistant ovarian tumor growth in vivo, the expression of PLK2 was quantified via qRT-PCR and Western blotting (Figure 5F,G). Here, PLK2 is linked to ovarian neoplasm.